Introduction
============

Despite the wide range of available treatments, rheumatoid arthritis (RA) continues to pose a substantial burden across the globe, with unmet needs in key domains such as pain, physical and mental functions, and fatigue. Although achievable outcomes for RA continue to evolve and improve, treatment goals and expectations are seldom fully met for patients and physicians alike.[@b1-ppa-12-1619] In 2012, Slim and Uthman[@b2-ppa-12-1619] reported that "treatment of rheumatic conditions in the Middle East and North Africa (MENA) region is still poorly addressed, inadequately funded and insufficiently reported in the national statistics of the MENA region, and Lebanon is no exception." A 2007 population-based survey conducted in 3,530 individuals aged over 15 years found a high burden of rheumatic diseases in Lebanon, with prevalence rate of RA being the most common at 1.0%.[@b3-ppa-12-1619] This high prevalence of rheumatic diseases merits urgent attention from national health care policymakers.

The prevalence of RA in the MENA region seems in the same range as in developed and industrialized countries.[@b4-ppa-12-1619] However, patients in developing nations, on average, are relatively more disabled than their counterparts in industrialized nations possibly due to lack of social resources and state support.[@b5-ppa-12-1619] Treatment strategy in RA aims to achieve remission or low disease activity as early as possible. Hence knowledge gaps in the extent and severity of RA in MENA countries could result in delays between symptom onset, referral, diagnosis, and the introduction of disease-modifying antirheumatic drugs (DMARDs), as well as low use of DMARDs and intensive therapy.[@b4-ppa-12-1619]

It is well known and conceptually implicit that patients will prefer to receive an oral drug over subcutaneous (SC) or intravenous (IV) injections/infusions. On the other hand, it is believed that adherence to treatment is lower with oral drugs than those given via SC/IV route. Understanding patient preferences over what treatments they wish to receive would help inform physicians and health authorities to make decisions in selecting and providing treatments that patients are likely to accept.[@b6-ppa-12-1619] Therefore, we aimed through a national survey to assess RA patients' preferences for the route of administration of DMARDs, and to identify the preferences determining factors.

Materials and methods
=====================

The LERACS (LEbanese Rheumatoid Arthritis Cohort Survey) study is a multicenter, cross-sectional patient survey that was designed to collect data on RA patients from private clinics and university hospitals. The 7 rheumatologists who participated in the study were practicing in various regions in Lebanon (central Beirut and other districts) and different settings (university teaching hospitals and private clinics); hence, it is believed that the data are fairly representative of the overall RA population in Lebanon.

The survey questionnaire was drafted by 2 rheumatologists (FF, NZ) based on a literature search, then presented and discussed with the group of participating rheumatologists for comments and final approval during a 4-hour meeting. The panel did not request patient input into the development of the questionnaire.

The questionnaire comprised 5 parts: demographics, disease characteristics, comorbidities, treatment preference, and reason for preference ([Supplementary material](#SD1-ppa-12-1619){ref-type="supplementary-material"}). The study was approved by the Ethical Committee of Hotel Dieu de France Hospital, affiliated to Saint Joseph University, Beirut/Lebanon. All patients gave written informed consent for this study.

Questionnaires were administered during medical consultations in the format of an interview between doctor and patient. Consecutive patients over a fixed 3-month period were asked about their use of RA treatments; their preferences for oral (no targeted synthetic DMARDs were available in Lebanon at the time the survey was undertaken), IV, or SC route; and the role of their physician in treatment decision-making. Data on patient demographics and disease characteristics were extracted from the medical records.

Results for categorical variables were summarized as means and percentages. For numerical variables, results were summarized using means and standard deviations or, in the case of variables with particularly skewed distributions, medians and interquartile ranges. Predetermined analyses, based on addressing questions of clinical importance, examined associations between variables using the *χ*^2^ test or Mann--Whitney *U* test. Where necessary, categories containing very few responses were combined with a similar category for the purposes of analysis. Univariable then multivariable analysis was used to assess variables that were significantly associated with treatment preferences. A *P*-value \<0.05 was regarded as statistically significant.

Results
=======

Patient and disease characteristics
-----------------------------------

Consecutive patients over a fixed 3-month period were invited to participate and a total of 693 patients completed the survey; all patients who were approached accepted the invitation to participate. [Table 1](#t1-ppa-12-1619){ref-type="table"} shows the patient demographics; most (83%) were female, 67% were aged between 41 and 70 years, 55% were unemployed, and only 12% had no health coverage. More than one-third (35%) of patients were smokers. [Table 2](#t2-ppa-12-1619){ref-type="table"} shows the patients' disease and treatment characteristics. A large proportion (80%) of patients had established RA (\>24 months); only 3% had very early disease (\<3 months). One-third (34%) of patients were in remission according to the disease activity score in 28 joints (DAS28). The median duration of symptoms was 6 (interquartile range, 3--13) years.

Current and previous experience with treatment
----------------------------------------------

A large majority (87%) of patients were receiving treatment with oral DMARDs ([Table 2](#t2-ppa-12-1619){ref-type="table"}); 60% received DMARDs by the oral route alone, and 27% used oral drugs in combination with IV or SC injections/infusions. Moreover, 43% (n=295) of patients took corticosteroids, 27% (n=184) nonsteroidal anti-inflammatory drugs, and 19% (n=130) other analgesics. In addition, 27% (n=185) of patients received antihypertensive drugs, 27% (n=183) antiosteoporosis agents, 19% (n=133) lipid-lowering drugs, and 11% (n=75) antidiabetic drugs; 43% (n=296) were on other comedication. A large proportion (84%; n=584) of patients had previously taken oral DMARDs, and 15% (n=104) tumor necrosis factor (TNF) inhibitors. Gastrointestinal intolerance was the most common drug side effect reported (18%; n=121), followed by liver toxicity (5%; n=36), hair loss (4%; n=29), and allergy (4%; n=27).

Patient preferences and their associations
------------------------------------------

The survey revealed that 64% of patients preferred oral over other routes of medication. A smaller number preferred IV or SC administration, while nearly one-quarter (22%) had no preference ([Table 2](#t2-ppa-12-1619){ref-type="table"}). More than half (53%; n=355) of the patients ranked doctor's advice as the most important influencing factor when choosing treatment, followed by the drug efficacy (27%; n=178), risk of side effects (10%; n=65), fear of injection (5%; n=32), insurance coverage (3%; n=23), and price (2%; n=15).

In univariable analyses of associations between various patient factors and expressing preference for oral route of administration, significant associations were found for health coverage (*P*\<0.001), radiographic damage (*P*\<0.001), disease duration (*P*=0.005), current therapy route (*P*\<0.001), and previous side effects (*P*=0.002) ([Table 3](#t3-ppa-12-1619){ref-type="table"}). Sex, age, smoking status, education, disease activity score, and number of medications were not significantly associated with patients' preference.

In multivariable analysis, only radiographic damage and current route of administration were independently associated with preference for oral therapy (both *P*\<0.001). Odds ratios were 0.27 (95% CI 0.15--0.49) for radiographic damage (vs no damage) and 8.97 (95% CI 4.35--18.5) for current oral route (vs current IV + IV/oral and SC + SC/oral) ([Table 4](#t4-ppa-12-1619){ref-type="table"}). Thus, those taking oral-only therapy were almost 9 times more likely than those on IV or IV/oral therapy to prefer oral administration.

Patients with radiographic damage were approximately 4 times less likely than those with no damage to prefer oral therapy.

Discussion
==========

This was the first study that analyzed treatment preferences in a large sample of RA patients in the MENA region. Patients in this region are managed following the same treatment strategies as those followed across Europe, most commonly the EULAR Guidelines. Most respondents to this survey of Lebanese RA patients expressed a preference for oral therapy. Preference for the oral route was significantly associated with lack of health coverage or radiographic damage, shorter disease duration, current oral therapy route, and no prior history of side effects. Independent associations with preference were found for radiographic damage and current oral route. The patients' treatment choices were influenced mainly by physician advice, followed by experience with current or previous treatments. The questionnaire used in this study was developed and validated only by rheumatologists with no patient input, which may be regarded as a minor limitation of this research.

Research from Europe demonstrates the importance of informing patients about RA and its treatment.[@b7-ppa-12-1619],[@b8-ppa-12-1619] In Norway, for example, high patient involvement in medical decision-making was associated with greater satisfaction with treatment received and better health status.[@b8-ppa-12-1619] Meanwhile, a Portuguese questionnaire study conducted in 223 RA patients found that as many as 68% reported that their rheumatologist was their preferred source of information about the disease and its treatment.[@b9-ppa-12-1619] Similar trends were observed in the present study: our surveyed patients were significantly more likely to prefer their current over alternative modes of treatment, and over half indicated that physician advice was the most influential factor when making decisions over treatment.

In 380 commercially insured RA patients surveyed in the US, route of administration was the most important attribute of RA treatment, followed by frequency of administration.[@b6-ppa-12-1619] Just over half (56%) the patients preferred oral route of administration over parenteral routes. In another US survey of 250 RA patients who had discontinued anti-TNF therapy, 41% cited injection experience (pain/burning/discomfort during or after injection, redness/swelling after injection, dislike of self-injection or of injection frequency, fear of needles) as an important reason for discontinuation.[@b10-ppa-12-1619] A German discrete-choice experiment performed in 1,588 RA patients found that "oral administration" and "no combination with methotrexate" were the most highly desired characteristics of a second-line DMARD, with "intravenous infusion" being among the most strongly rejected.[@b11-ppa-12-1619] The authors concluded that an oral DMARD excluding methotrexate is a highly favorable treatment option that may increase compliance and adherence in RA treatment.

The present large-scale survey conducted in nearly 700 patients with RA similarly confirmed a strong preference for oral rather than SC/IV administration of drugs in those who were already taking oral agents, whereas the proportions of patients taking parenterally administered drugs were similar to the rates of expressing a preference for these routes of administration, suggesting that patient satisfaction that SC/IV drugs, which are usually prescribed for more advanced disease, could improve their condition overrode their reluctance to receive injections/infusions. These findings were also echoed in our observation that the presence of radiographic damage was significantly associated with an approximately 4 times lower risk of preference for oral drugs; patients with more severe disease seem to want more potent treatments regardless of route of administration. This may be because these patients may prefer to visit a hospital to receive an infusion (perhaps in order to have interactions with health care professionals), have concerns about their ability to adhere to an oral medicine, or believe an injection or infusion is more powerful than an oral alternative, particularly as there are few oral therapies for moderate-to-severe ulcerative colitis currently available.[@b12-ppa-12-1619]

Conclusion
==========

Lebanese RA patients expressed a high preference for oral agents, and mostly cited physician advice as the most important influencing factor in their treatment decisions. When making funding decisions, policymakers are encouraged to consider patients' requirements, experiences, goals, and preference, so understanding patients' preferences may help to inform health care policymakers in providing a selection of treatments.[@b13-ppa-12-1619]
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Patient questionnaire.

**Abbreviations:** RA, rheumatoid arthritis; NSAID, nonsteroidal anti-inflammatory drug; DMARD, disease-modifying antirheumatic drug.
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###### 

Demographic characteristics of patients (n=693)

  Variable              \% of patients
  --------------------- ----------------
  Age (years)           
   ≤30                  7.2
   31--40               10.2
   41--50               20.2
   51--60               **28.7**
   61--70               20.3
   71--80               10.8
   ≥81                  2.7
  Female                83.0
  Current smoker        34.6
  Arab ethnicity        99.0
  Employment status     
   Full-time employed   27.6
   Part-time employed   6.1
   Self-employed        9.2
   Student              1.4
   Retired              0.8
   Unemployed           **55**

**Notes:** n=693 is the pooled total, with some responses missing in some categories. The bold values indicate the highest percentage among all age groups and employment status.

###### 

Disease and treatment characteristics (n=693 patients)

  Variable                              \% of patients
  ------------------------------------- ----------------
  Disease stage                         
   Very early (\<3 months)              3.1
   Early (3--24 months)                 17.3
   Established (\>24 months)            **79.6**
  Disease activity score in 28 joints   
   Remission (≤2.6)                     **34.2**
   Low (2.7--3.2)                       23.2
   Moderate (3.3--5.1)                  32.9
   High (\>5.1)                         9.7
  Radiographic damage                   
   Yes                                  44.6
   No                                   **55.4**
  Length of symptoms (since onset)      
   \<5 years                            **39.0**
   5--9 years                           25.0
   10--19 years                         26.0
   ≥20 years                            10.1
  Current medication^a^                 
   Oral DMARD                           **87.0**
   TNF inhibitor                        25.0
   Other biologic                       15.7
  Route of DMARD administration         
   Intravenous                          4.6
   Oral                                 **59.2**
   Subcutaneous                         9.3
   Oral + intravenous                   13.4
   Oral + subcutaneous                  13.4
  Patient preference                    
   IV                                   6.2
   Oral                                 **63.6**
   SC                                   8.3
   No preference                        21.9

**Notes:** n=693 is the pooled total, with some responses missing in some categories. The bold values indicate the highest percentage among each category.

**Abbreviations:** DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor; IV, intravenous; SC, subcutaneous.

###### 

Univariable analysis of factors associated with patient preference administration route

  Variable               Number (%) preferred oral   Odds ratio (95% CI)   *P*-value
  ---------------------- --------------------------- --------------------- -------------
  Age (years)                                                              0.67
   ≤30                   29/33 (87.9)                1                     
   31--40                39/53 (73.6)                0.38 (0.11--1.29)     
   41--50                83/101 (82.2)               0.64 (0.20--2.03)     
   51--60                126/154 (81.8)              0.62 (0.20--1.91)     
   61--70                85/106 (80.2)               0.56 (0.18--1.76)     
   ≥71                   62/75 (82.7%)               0.66 (0.20--2.19)     
  Sex                                                                      0.80
   Female                358/441 (81.2)              1                     
   Male                  70/85 (82.4)                1.08 (0.59--1.98)     
  Smoker                                                                   0.33
   No                    267/334 (79.9)              1                     
   Yes                   156/187 (83.4)              1.26 (0.79--2.02)     
  Education                                                                0.56
   None                  102/128 (79.7)              1                     
   High school           193/239 (80.8)              1.07 (0.62--1.83)     
   Undergraduate         70/86 (81.4)                1.12 (0.56--2.23)     
   Postgraduate          56/64 (87.5)                1.78 (0.76--4.20)     
  Health coverage                                                          \<**0.001**
   None                  65/68 (95.6)                1                     
   Partial               179/220 (81.4)              0.20 (0.06--0.67)     
   Full                  178/230 (77.4)              0.16 (0.05--0.52)     
  DAS category                                                             0.84
   Remission             141/162 (87.0)              1                     
   Low                   97/114 (85.1)               0.85 (0.43--1.69)     
   Moderate              120/144 (83.3)              0.74 (0.39--1.40)     
   High                  258/33 (84.9)               0.83 (0.29--2.40)     
  Radiographic damage                                                      \<**0.001**
   No                    238/259 (91.9)              1                     
   Yes                   143/196 (73.0)              0.24 (0.14--0.41)     
  Current route                                                            \<**0.001**
   IV + IV/oral          44/77 (57.1)                1                     
   SC + SC/oral          53/97 (54.6)                0.90 (0.49--1.65)     
   Oral                  315/336 (93.8)              11.3 (5.98--21.2)     
  Number of pills/d                                                        0.41
   0                     54/67 (80.6)                1                     
   1--3                  178/226 (78.8)              0.89 (0.45--1.77)     
   4--9                  160/192 (83.3)              1.20 (0.59--2.46)     
   ≥10                   37/42 (88.1)                1.78 (0.59--5.42)     
  Previous side effect                                                     **0.002**
   No                    324/383 (84.6)              1                     
   Yes                   105/144 (72.9)              0.49 (0.31--0.78)     

**Note:** Bold *P*-values indicate statistically significant.

**Abbreviations:** IV, intravenous; SC, subcutaneous.

###### 

Multivariable analysis of factors associated with patient preference administration route

  Variable              Category                Odds ratio (95% CI)   *P*-value
  --------------------- ----------------------- --------------------- -----------
  Radiographic damage   No                      1                     \<0.001
  **Yes**               **0.27 (0.15--0.49)**                         
  Current route         IV + IV/oral            1                     \<0.001
  SC + SC/oral          1.03 (0.53--2.08)                             
  **Oral**              **8.97 (4.35--18.5)**                         

**Note:** Bold values indicate modal values.

**Abbreviations:** IV, intravenous; SC, subcutaneous.
